## Active Research Studies at Corewell Health West

Pediatrics Pulmonary	
STOP360-IP-22	Standardizing Treatments for Pulmonary Exacerbations: A platform for evaluating treatment decisions to improve outcomes (STOP360-IP-22)
TITANIA NCT05158387	A phase III Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled study to evaluate the efficacy and safety of two dose regimens of MEDI3506 in participants with COPD.
Vertex 104	Open label study for VX20-121-102 and VX20-121-103